Immunovia AB (FRA:1YR)
€ 0.0338 0.0013 (4%) Market Cap: 8.99 Mil Enterprise Value: 6.59 Mil PE Ratio: 0 PB Ratio: 2.83 GF Score: 42/100

Immunovia AB (publ) - Special Call Transcript

Sep 09, 2019 / 04:30PM GMT
Operator

Welcome to Immunovia's live webinar entitled differentiating pancreatic ductal adenocarcinoma from individuals with symptoms suggestive of PDAC, including type 2 diabetes, with ROC AUC values above 0.95. Thank you for joining us.

Before we get started, I would like to take a moment to acquaint you with a few features of this web event technology. At any time, you may adjust your audio using any computer volume settings that you may have. On the right-hand side of your screen, you will see the text chat window. There is a large window, which holds all of your sent messages and a smaller text box at the bottom where you will type in your questions. (Operator Instructions)

We are joined today by our speakers, Linda Mellby, Immunovia's Vice President of Research and Development; and Dr. Thomas King, Immunovia's Medical Director.

At this time, I would like to turn the microphone over to our first presenter, Linda Mellby.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot